Hsiang-Chun Lin1, Chao-Liang Wu1, Yuh-Ling Chen2, Jehn-Shyun Huang2,3, Tung-Yiu Wong2,3, Kuo Yuan4,5. 1. Department of Biochemistry and Molecular Biology, College of Medicine, National Cheng Kung University, Tainan, Taiwan. 2. Institute of Oral Medicine, College of Medicine, National Cheng Kung University, 1 University Road, Tainan, 701, Taiwan. 3. Department of Stomatology, National Cheng Kung University Hospital, Tainan, Taiwan. 4. Institute of Oral Medicine, College of Medicine, National Cheng Kung University, 1 University Road, Tainan, 701, Taiwan. kuoyuan@mail.ncku.edu.tw. 5. Department of Stomatology, National Cheng Kung University Hospital, Tainan, Taiwan. kuoyuan@mail.ncku.edu.tw.
Abstract
OBJECTIVES: The β1 integrin (CD29) is a putative marker for cancerous epithelial stem cells. Cancer stem cells are essential to drive tumor growth, recurrence, and metastasis. We investigated the role of β1-integrin expression in the development of malignant phenotypes of oral squamous cell carcinoma (OSCC). MATERIALS AND METHODS: Immunostaining was used to analyze the expression levels of β1 integrins in different types of cell colonies and tumor spheres. The results of cell viability and migration assays with and without siRNA knockdown of β1-integrin expression were compared. Cells expressing β1 integrins were evaluated for their tumorigenicity in mice. The expression of β1 integrins in human specimens of oral cancers at different clinical stages was semiquantified based on immunohistochemical staining of the β1-integrin protein. RESULTS: The expression level of β1 integrins in Meng-1 oral epidermoid carcinoma cells (OECM-1) cells was significantly higher in holoclonal colonies and tumor spheres compared to control cells. The knockdown of β1-integrin expression in OECM-1 cells reduced cell proliferation, migration, and tumor sphere formation. Beta-1 integrin (+) cells were more tumorigenic in the mouse xenograft model than β1 integrin (-) cells. In the human specimens, the expression level of the β1-integrin protein positively correlated with the clinical stage. CONCLUSION: The expression of β1 integrin in OECM-1 cells is involved in the development of malignant phenotypes of OSCC. CLINICAL RELEVANCE: Inhibitors for β1-integrin signaling may be suitable to become target-specific therapies for OSCC.
OBJECTIVES: The β1 integrin (CD29) is a putative marker for cancerous epithelial stem cells. Cancer stem cells are essential to drive tumor growth, recurrence, and metastasis. We investigated the role of β1-integrin expression in the development of malignant phenotypes of oral squamous cell carcinoma (OSCC). MATERIALS AND METHODS: Immunostaining was used to analyze the expression levels of β1 integrins in different types of cell colonies and tumor spheres. The results of cell viability and migration assays with and without siRNA knockdown of β1-integrin expression were compared. Cells expressing β1 integrins were evaluated for their tumorigenicity in mice. The expression of β1 integrins in human specimens of oral cancers at different clinical stages was semiquantified based on immunohistochemical staining of the β1-integrin protein. RESULTS: The expression level of β1 integrins in Meng-1 oral epidermoid carcinoma cells (OECM-1) cells was significantly higher in holoclonal colonies and tumor spheres compared to control cells. The knockdown of β1-integrin expression in OECM-1 cells reduced cell proliferation, migration, and tumor sphere formation. Beta-1 integrin (+) cells were more tumorigenic in the mouse xenograft model than β1 integrin (-) cells. In the human specimens, the expression level of the β1-integrin protein positively correlated with the clinical stage. CONCLUSION: The expression of β1 integrin in OECM-1 cells is involved in the development of malignant phenotypes of OSCC. CLINICAL RELEVANCE: Inhibitors for β1-integrin signaling may be suitable to become target-specific therapies for OSCC.
Authors: O Felthaus; T Ettl; M Gosau; O Driemel; G Brockhoff; A Reck; K Zeitler; M Hautmann; T E Reichert; G Schmalz; C Morsczeck Journal: Biochem Biophys Res Commun Date: 2011-02-20 Impact factor: 3.575
Authors: P Maragou; E Bazopoulou-Kyrkanidou; E Panotopoulou; E Kakarantza-Angelopoulou; A Sklavounou-Andrikopoulou; S Kotaridis Journal: Oral Dis Date: 1999-01 Impact factor: 3.511
Authors: Donald R Senger; Carole A Perruzzi; Michael Streit; Victor E Koteliansky; Antonin R de Fougerolles; Michael Detmar Journal: Am J Pathol Date: 2002-01 Impact factor: 4.307
Authors: Xin Zhang; Yanna Liu; Michael Z Gilcrease; Xiao H Yuan; Gary L Clayman; Karen Adler-Storthz; Zhuo Chen Journal: Cancer Date: 2002-10-15 Impact factor: 6.860
Authors: Oneida A Arosarena; Raul A Dela Cadena; Michael F Denny; Evan Bryant; Eric W Barr; Ryan Thorpe; Fayez F Safadi Journal: J Cell Physiol Date: 2016-02-08 Impact factor: 6.384